Home / Healthcare / Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Published: Jun 2015 | No Of Pages: 137 | Published By: Global Markets Direct

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Skin And Soft Tissue Infections - Pipeline Review, H1 2015', provides an overview of the Skin And Soft Tissue Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Skin And Soft Tissue Infections Overview 10
Therapeutics Development 11
Pipeline Products for Skin And Soft Tissue Infections - Overview 11
Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis 12
Skin And Soft Tissue Infections - Therapeutics under Development by Companies 13
Skin And Soft Tissue Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Skin And Soft Tissue Infections - Products under Development by Companies 20
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development 22
Allergan Plc 22
Atox Bio Inc. 23
Cempra, Inc. 24
CorMedix, Inc. 25
CrystalGenomics, Inc. 26
Debiopharm International S.A. 27
Dong-A Socio Group 28
GlaxoSmithKline Plc 29
Melinta Therapeutics, Inc 30
MicuRx Pharmaceuticals, Inc. 31
Motif Bio Plc 32
Nabriva Therapeutics AG 33
NovaDigm Therapeutics, Inc. 34
Phosphagenics Limited 35
Takeda Pharmaceutical Company Limited 36
Tetraphase Pharmaceuticals Inc. 37
The Medicines Company 38
Wockhardt Limited 39
Skin And Soft Tissue Infections - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
AB-103 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
acorafloxacin hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BC-7013 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ceftaroline fosamil - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CG-400549 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CRMD-004 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Debio-1450 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Debio-1452 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
delafloxacin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
eravacycline - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
fusidic acid - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
gepotidacin mesylate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
iclaprim mesylate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
IOG-101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
KBP-7072 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
lefamulin - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MRX-I - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Mul-1867 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
NDV-3 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Nu-2 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
oritavancin diphosphate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
radezolid - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
siderocillin - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule for Skin Infections - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
tedizolid phosphate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
VAL-301 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
WCK-2349 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Skin And Soft Tissue Infections - Recent Pipeline Updates 97
Skin And Soft Tissue Infections - Dormant Projects 126
Skin And Soft Tissue Infections - Discontinued Products 128
Skin And Soft Tissue Infections - Product Development Milestones 129
Featured News & Press Releases 129
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority 129
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections 129
Aug 05, 2014: Cubist's Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations 130
Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections 131
Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review 132
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial 132
Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections 133
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections 134
May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC 134
Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America 135
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

Number of Products under Development for Skin And Soft Tissue Infections, H1 2015 11
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Comparative Analysis by Unknown Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Skin And Soft Tissue Infections - Pipeline by Allergan Plc, H1 2015 22
Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H1 2015 23
Skin And Soft Tissue Infections - Pipeline by Cempra, Inc., H1 2015 24
Skin And Soft Tissue Infections - Pipeline by CorMedix, Inc., H1 2015 25
Skin And Soft Tissue Infections - Pipeline by CrystalGenomics, Inc., H1 2015 26
Skin And Soft Tissue Infections - Pipeline by Debiopharm International S.A., H1 2015 27
Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H1 2015 28
Skin And Soft Tissue Infections - Pipeline by GlaxoSmithKline Plc, H1 2015 29
Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 30
Skin And Soft Tissue Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 31
Skin And Soft Tissue Infections - Pipeline by Motif Bio Plc, H1 2015 32
Skin And Soft Tissue Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 33
Skin And Soft Tissue Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2015 34
Skin And Soft Tissue Infections - Pipeline by Phosphagenics Limited, H1 2015 35
Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 36
Skin And Soft Tissue Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 37
Skin And Soft Tissue Infections - Pipeline by The Medicines Company, H1 2015 38
Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H1 2015 97
Skin And Soft Tissue Infections - Dormant Projects, H1 2015 126
Skin And Soft Tissue Infections - Dormant Projects (Contd..1), H1 2015 127
Skin And Soft Tissue Infections - Discontinued Products, H1 2015 128

Number of Products under Development for Skin And Soft Tissue Infections, H1 2015 11
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Products, H1 2015 18
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Top 10 Targets, H1 2015 41
Number of Products by Stage and Top 10 Targets, H1 2015 41
Number of Products by Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Top 10 Routes of Administration, H1 2015 45
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 45
Number of Products by Top 10 Molecule Types, H1 2015 47
Number of Products by Stage and Top 10 Molecule Types, H1 2015 47

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +